Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Dr. Peter Salzmann M.B.A., M.D.

Market Cap

2.45 Billion USD

Sector

Healthcare

Website

https://immunovant.com

Description

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.

Read More

Overview

Value

2

Growth

2

Health

52

Management

59

Analyst Opinion

60

Total

34

All Scores Out Of 100

Best Features

  • Has a low level of debt
  • Low preportion of income is paid as dividend
  • 0

Risk Factors

  • Overvalued on cashflow basis
  • Earnings have declined recently
  • Income is not covering expenditure and investment
  • Earnings are negative
  • There is a history of diluting shareholders
  • No margin of safety at their current market price
  • Disliked by Twitter users
  • Poor earnings and cashflow growth

Market Peers

IMVT

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

-83.49%

Revenue Growth (5 Year Average)

N/A

Ratings Consensus

Neutral

Share Buybacks

-106.26%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

2

  • Estimated intrinsic-value of 3.14 USD is lower than current price ( 19.00 USD)
  • Free-cashflow-yeild of -6.75% is worse than the market average (4.7%)
  • Margin-of-safety of -83.49% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 3.2 USD

Current Price: 19 USD

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-6.75%

PE/Earnings Growth

N/A

Price/Book

5.92x

Growth

Growth Score

2

  • Revenue growth has improved this yeara
  • 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
  • 5 Year Average Earnings growth of 0.36% is lower than the market average (14.48%)
  • Earnings growth has slowed this year
  • 5 Year Average Free Cashflow growth of -20.38% is lower than the market average (12.35%)
  • Free Cashflow growth has slowed this year

Revenue Growth

N/A

Earnings Growth

0.36%

Cashflow Growth

-20.38%

Health

Health Score

52

  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Cashflow is negative
  • Debt repayments significantly impact cashflow

Altman Z Score

N/A

Piostroski Score

N/A

Debt/Equity

0.01x

Current Assets/Liabilities

11.52x

Free Cashflow/Total Debt

N/Ax

Debt/Capital

0.00x

Management

Management Score

59

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of -27.95% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of -39.32% is lower than the market average (15%)

Average Buybacks/Dilution

-106.26%

Recent Buybacks/Dilution

17.78%

5 Year Price Volitility

77.00%

Return On Assets

-35.83%

Return On Capital Employed

-27.95%

Return On Equity

-39.32%

Return On Free Cashflow

221.14%

Return On Investments

N/A

Social Sentiment

Social Sentiment Score

26

Twitter Sentiment

N/A

Stocktwits Sentiment

51.00

Analysts

Analyst Opinion

60

  • Ratings consensus is Neutral

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Immunovant, Inc.

Currency

USD

Beta

1.087135

Vol Avg

1195632

Ceo

Dr. Peter Salzmann M.B.A., M.D.

Cik

0001764013

Cusip

45258J102

Exchange

NASDAQ Global Select

Full Time Employees

124

Industry

Biotechnology

Sector

Healthcare

Ipo Date

2019-05-10

Address

320 West 37Th Street

City

New York City

State

NEW YORK

Country

US

Zip

10018

Phone

19175803099

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies